Microbial identification for an effective biocleaning: the case study of the Santa Lucia alle Malve rupestrian church

Identifying the microbial community that lives on the lithic cultural heritage through phenotypic and genotypic approaches is fundamental for understanding the contribution of colonisers in biodeterioration and selecting the best cleaning solutions with environmentally-friendly products. This was done with the cultivable microbiota present on the internal walls of the Santa Lucia alle Malve (SLM) rock church, recognised by UNESCO as a World Heritage Site. The SLM church is in the Sasso Caveoso area (Matera, South Italy). It is fully excavated in the limestone rock. Numerous frescoes cover the internal surfaces, but the bacterial and fungal colonisation spoils its beauty. The results of this study clearly showed the predominance of bacteria of the phylum Firmicutes and precisely of the genus Bacillus, whose prevalence may be due to the specific environmental conditions, very similar in all sampling sites of the church, and to their ability to produce endospores. These dormant forms allow bacteria to survive in unfavourable conditions. The genotypic approach showed that the various Bacillus species isolated on the surfaces of the experimented church are closely related and similar but show a different phenotypic profile. This diversity of physiological and morphological traits reflects the potential complexity of the metabolomes present in the bacterial communities of the internal walls of the SLM and confirms the need to identify the colonisers correctly and proceed with a non-temporary bio-cleaning. The results of bio-cleaning using Solanum nigrum extracts were effective, but the durability of the treatment has yet to be verified

Microbial identification for an effective biocleaning: the case study of the Santa Lucia alle Malve rupestrian church

Identifying the microbial community that lives on the lithic cultural heritage through phenotypic and genotypic approaches is fundamental for understanding the contribution of colonisers in biodeterioration and selecting the best cleaning solutions with environmentally-friendly products. This was done with the cultivable microbiota present on the internal walls of the Santa Lucia alle Malve (SLM) rock church, recognised by UNESCO as a World Heritage Site. The SLM church is in the Sasso Caveoso area (Matera, South Italy). It is fully excavated in the limestone rock. Numerous frescoes cover the internal surfaces, but the bacterial and fungal colonisation spoils its beauty. The results of this study clearly showed the predominance of bacteria of the phylum Firmicutes and precisely of the genus Bacillus, whose prevalence may be due to the specific environmental conditions, very similar in all sampling sites of the church, and to their ability to produce endospores. These dormant forms allow bacteria to survive in unfavourable conditions. The genotypic approach showed that the various Bacillus species isolated on the surfaces of the experimented church are closely related and similar but show a different phenotypic profile. This diversity of physiological and morphological traits reflects the potential complexity of the metabolomes present in the bacterial communities of the internal walls of the SLM and confirms the need to identify the colonisers correctly and proceed with a non-temporary bio-cleaning. The results of bio-cleaning using Solanum nigrum extracts were effective, but the durability of the treatment has yet to be verified

Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis : a randomised, double-blind, placebo-controlled trial

BACKGROUND: This multicentre, randomised, double-blind, placebo-controlled trial was performed to determine whether the use of oral probiotic preparation (prOVag®) containing three Lactobacillus strains together with standard metronidazole treatment and also targeted antibiotic treatment (following the failure of metronidazole therapy) could reduce the recurrence rates of bacterial vaginosis (BV) and aerobic vaginitis (AV). METHODS: Patients at private gynaecological clinics in Poland with histories of recurrent BV/AV and current symptoms were randomly allocated to receive metronidazole and probiotic or placebo, and assessed monthly on visits II and III-V. The total number of study visits was 5–6 (I, II, II bis – if applicable, III, IV, V). One probiotic or placebo capsule was administered with metronidazole/targeted antibiotic twice daily for 10 days; during follow up, patients took one capsule daily for 10 days perimenstrually. Clinical examination and vaginal swabbing were performed at each visit. Primary outcomes were clinical or microbiological BV/AV recurrence and probiotic safety. Secondary outcomes were vaginal pH, Nugent score, and Lactobacillus counts in the vaginal microbiota. Safety analysis was performed in 578 (probiotic, n = 285; placebo, n = 293) 18–50-year-old women who were randomised. RESULTS: BV/AV was confirmed microbiologically in 241 (probiotic, n = 118; placebo, n = 123) participants, who continued the trial. Data from 154 (probiotic, n = 73; placebo, n = 81) participants who completed the study were analysed to determine the efficacy of prOVag. Additional analyses included 37 (probiotic, n = 22; placebo, n = 15) participants who received targeted antibiotics and probiotics or placebo. prOVag lengthened the time to clinical relapse of BV/AV symptoms up to 51 % (p < 0.05) compared with placebo; AV relapse was delayed by up to 76 % (p < 0.05). Probiotic use also reduced and maintained low vaginal pH and Nugent score, and increased vaginal Lactobacillus counts following standard treatment. CONCLUSION: This study demonstrated that oral probiotics lengthened remission in patients with recurrent BV/AV and improved clinical and microbiological parameters. TRIAL REGISTRATION: NCT01993524; 20 November 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12905-015-0246-6) contains supplementary material, which is available to authorized users

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study

© 2021 Via Medica. This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license. https://creativecommons.org/licenses/by/4.0/The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of DAPT without depriving it of its efficacy have been evaluated so far. We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved anti-ischemic benefit may also be expected with additional acetylsalicylic acid (ASA) withdrawal. To evaluate these hypotheses, we designed the Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome — a randomized clinical trial (ELECTRA-SIRIO 2), to assess the influence of ticagrelor dose reduction with or without continuation of ASA versus DAPT with standard dose ticagrelor in reducing clinically relevant bleeding and main-taining anti-ischemic efficacy in ACS patients. The study was designed as a phase III, randomized, multicenter, double-blind, investigator-initiated clinical study with a 12-month follow-up.Peer reviewedFinal Published versio

Energy relations in antiferroelectric liquid crystals

C

Uniform theory of V-shape characteristics

C